CellMinerCDB

Cell Line Metadata

To download a copy of this information click [MS-Excel] or [text].
Cell Name Tissue of Origina Agea Sexa Prior Treatmenta,b Epithelial Histologya,c Source Ploidyd p53 Functione mdrf Doubling Timeg Institute Contributor Reference Fingerprint linkh
BR:MCF7 Breast 69 F NA no Adenocarcinoma- mammary gland; breast; metastatic site: pleural effusion; Pleural effusion 3n-, Hypotriploid (58-68) WT 14 25.4 Michigan Cancer Foundtion C.M. McGrath JNCI 51: 1409-1417,1973 fingerprint
BR:MDA-MB-231 Breast 51 F NA no Adenocarcinoma-mammary gland; breast; epithelial; metastatic site: pleural effusion; Pleural effusion 2n+, Hyperdiploid (47-57) MT 29 41.9 MD Anderson Hospital and Tumor Institute R. Cailleau JNCI 53(3): 661-674,1974 fingerprint
BR:HS 578T Breast 74 F NA no Carcinosarcoma-mammary gland; breast Primary 2n+, Hyperdiploid (47-57) MT NA 53.8 Naval Bioscience Laboratory A.J. Hackett JNCI 58: 1795-1806,1977 fingerprint
BR:BT-549 Breast 72 F NA no Papillary infiltrating ductal carcinoma-mammary gland; breast Metastasis 3n+/-, Near-triploid 69+/- (58-80) ? -45 53.9 - W. Coutinho; E.Y. Lasfargues no pub fingerprint
BR:T-47D Breast 54 F NA no infiltrating ductal carcinoma NA 2n+, Hyperdiploid (47-57) MT 19 45.5 - I. Keydar Eur J Cancer 15:659-679,1979 fingerprint
CNS:SF-268 Central nervous system 24 F Rad yes Glioblastoma, ud NA 2n+, Hyperdiploid (47-57) MT -38 33.1 - P.L.Kornblith Acta Neuropathol 75: 92-103, 1987 fingerprint
CNS:SF-295 Central nervous system 67 F Rad yes Glioblastoma, ud NA 5n+/-, Near-pentaploid 115+/- (104-126) MT 91 29.5 University of California M.L. Rosenblum Acta Neuropathol 75: 92-103, 1988 fingerprint
CNS:SF-539 Central nervous system 34 F Rad/BCNU/5FU/HU/6MP yes Glial cell neoplasm NA 4n+/-, Near-tetraploid 92+/- (81-103) WT -40 35.4 University of California M.L. Rosenblum J Neuropathol Exp Neurol 40: 201-229, 1981 fingerprint
CNS:SNB-19 Central nervous system 47 M None yes Glioblastoma, ud NA 3n+/-, Near-triploid 69+/- (58-80) MT -41 34.6 NINCDS P.L. Kornblith Cancer 47: 255, 1981 fingerprint
CNS:SNB-75 Central nervous system NA F None yes Astrocytoma NA 2n+, Hyperdiploid (47-57) MT -38 62.8 NINCDS P.L. Kornblith Can Res 48:589-601, 1988 fingerprint
CNS:U251 Central nervous system 75 M NA yes Glioblastoma,ud NA 2n+, Hyperdiploid (47-57) MT -19 23.8 University of Uppsala, Sweden - J Neuropathol Exp Neurol 40: 410-427, 1981 fingerprint
CO:COLO 205 Colon 70 M NA no Adenocarcinoma Ascites 3n, Triploid (69) MT 7 23.8 enver Medical Hospital G.E. Moore Cancer Res. 38: 1345-1355, 1978 fingerprint
CO:HCC-2998 Colon NA NA NA no carcinoma NA 2n+/-, Near-diploid 46+/- (35-57) MT -5 31.5 MD Anderson Hospital and Tumor Institute I.J. Fidler - fingerprint
CO:HCT-116 Colon NA M NA no carcinoma-vpd NA 2n-, Hypodiploid (35-45) ? 26 17.4 Baylor College - Cancer Res 41: 1761-1756, 1981 fingerprint
CO:HCT-15 Colon NA NA None no Adenocarcinoma p/md NA 2n+/-, Near-diploid 46+/- (35-57) ? 414 20.6 ATCC ATCC (D.L. Dexter, Roger Williams General Hospital) Cancer Res 39: 1020-1025, 1979 fingerprint
CO:HT29 Colon 44 F None no Adenocarcinoma-md Primary 3n+/-, Near-triploid 69+/- (58-80) MT 15 19.5 Memorial Sloan Kettering Cancer Center J. Fogh Human Tumor Cells in vitro: 115-159, 1975 fingerprint
CO:KM12 Colon NA NA None no Adenocarcinome-pd NA 2n+/-, Near-diploid 46+/- (35-57) MT -19 23.7 MD Anderson Hospital and Tumor Institute I.J. Fidler, Univ of Texas M.D. Anderson Hospital and Tumor Institute Cancer Res 48: 1943-1948, 1988 fingerprint
CO:SW-620 Colon 51 M NA no Carcinoma-ud NA 2n+/-, Near-diploid 46+/- (35-57) MT 31 20.4 Scott White Clinic A. Leibovitz Cancer Res 1976 Dec;36(12):4562-9 fingerprint
LE:CCRF-CEM Leukemia 4 F Rad/Mtx/Ctx yes ALL NA 2n+/-, Near-diploid 46+/- (35-57) MT 35 26.7 Children's Cancer research Foudation G.E. Foley Cancer 18: 522-529, 1965 fingerprint
LE:HL-60(TB) Leukemia 36 F None yes Pro myelocytic leukemia PBL 2n+/-, Near-diploid 46+/- (35-57) MT -11 28.6 NCI R.C. Gallo Blood 54(3):713-33, 1979 fingerprint
LE:K-562 Leukemia 53 F Bisulfan/PiBr yes CML Pleural effusion 3n-, Hypotriploid (58-68) MT -1 19.6 University of Tennesse H.T. Holden Blood 45: 321-334, 1975 fingerprint
LE:MOLT-4 Leukemia 19 M VB/6MP/Pred yes ALL (cells were taken when patient was in relapse) PB 4n, Tetraploid (92) WT 10 27.9 Roswell Park Memorial Institute J. Minowada J. Natl. Cancer Inst. 49: 891-895, 1972 fingerprint
LE:RPMI-8226 Leukemia 61 M None yes Myeloma PB 3n-, Hypotriploid (58-68) WT -3 33.5 - G.E. Moore Proc Soc Exp Biol Med 125: 1246-1250, 1967 fingerprint
LE:SR Leukemia 11 M None yes Lymphoma NA 2n+/-, Near-diploid 46+/- (35-57) ? 4 28.7 Program Resources, Inc. W.J. Urba, Program Resources, Inc. - fingerprint
ME:LOX IMVI i Melanoma 58 M None yes Malignant amelanotic melanoma NA 3n+/-, Near-triploid 69+/- (58-80) WT 12 20.5 Norsk Hydro's Institut, Norway O. Fodstad Int J Cancer 41: 442-449, 1988 fingerprint
ME:MALME-3M Melanoma 43 M None yes Malignant melanotic melanoma Metastasis 4n+/-, Near-tetraploid 92+/- (81-103) WT 22 46.2 Memorial Sloan Kettering Cancer Center J. Fogh J. Natl. Cancer Inst. 59: 221-226, 1977 fingerprint
ME:M14 Melanoma NA NA NA yes Melanotic melanoma NA 3n+/-, Near-triploid 69+/- (58-80) MT 14 26.3 John Wayne Cancer Clinic, UCLA School of Medicine D.H. Kern, John Wayne Cancer Clinic, UCLA School of Medicine Cancer Res 48: 578-582, 1988 fingerprint
ME:SK-MEL-2 Melanoma 60 M None yes Malignant melanotic melanoma Metastasis 4n-, Hypotetraploid (81-91) WT 14 45.5 Memorial Sloan Kettering Cancer Center G. Trempe; L.J. Old Human Tumor Cells in vitro, pp 115-159, 1975 fingerprint
ME:SK-MEL-28 Melanoma 51 M None yes Malignant melanotic melanoma NA 4n-, Hypotetraploid (81-91) MT 11 35.1 Memorial Sloan Kettering Cancer Center T. Takahashi PNAS 73: 3278-3282, 1976 fingerprint
ME:SK-MEL-5 Melanoma 24 F None yes Malignant melanotic melanoma Metastasis 4n+, Hypertetraploid (93-103) WT 12 25.2 Memorial Sloan Kettering Cancer Center T. Takahashi PNAS, 73: 3278-3282, 1976 fingerprint
ME:UACC-257 Melanoma NA NA NA yes Melanotic melanoma NA 3n+, Hypertriploid (70-80) WT 26 38.5 University of Arizona A. Leibovitz, UACC - fingerprint
ME:UACC-62 Melanoma NA NA NA yes Melanotic melanoma NA 3n+/-, Near-triploid 69+/- (58-80) WT 8 31.3 University of Arizona A. Leibovitz, UACC - fingerprint
ME:MDA-MB-435 j Melanoma 31 F NA yes Ductal carcinoma- mammary gland; breast; duct; metastatic site: pleural effusion; Pleural effusion 2n+, Hyperdiploid (47-57) MT 20 25.8 - R. Cailleau Cancer Res 40:3118-3129,1980 fingerprint
ME:MDA-N k Melanoma 31 F NA yes Ductal carcinoma- mammary gland; breast; duct; metastatic site: pleural effusion; Pleural effusion NA MT 12 22.5 - - - fingerprint
LC:A549/ATCC Non-Small Cell Lung 58 M NA no Adenocarcinoma-p/md NA 3n+/-, Near-triploid 69+/- (58-80) WT 10 22.9 NCI Giard DJ J Natl Cancer Inst. 51(5):1417-23, 1973 fingerprint
LC:EKVX Non-Small Cell Lung NA M NA no Adenocarcinoma-md NA 3n+/-, Near-triploid 69+/- (58-80) MT -9 43.6 Norsk Hydro's Institut, Norway O. Fodstad - fingerprint
LC:HOP-62 Non-Small Cell Lung 60 F None no adenocarcinoma-ud NA 4n+, Hypertetraploid (93-103) MT 61 39 Johns Hopkins University M.Liu - fingerprint
LC:HOP-92 Non-Small Cell Lung 62 M None no Large cell-ud NA 4n+/-, Near-tetraploid 92+/- (81-103) MT -4 79.5 Johns Hopkins University M.Liu - fingerprint
LC:NCI-H226 Non-Small Cell Lung NA M None (non smoker) no Squamous cell carcinoma-vpd NA 3n, Triploid (69) MT 7 61 NCI J.D. Minna; A.F. Gazdar Cancer Res. 40: 3502-3507, 1980 fingerprint
LC:NCI-H23 Non-Small Cell Lung NA M None no Adenocarcinoma-ud NA 2n+, Hyperdiploid (47-57) MT -2 33.4 NCI J.D. Minna; A.F. Gazdar Cancer Res. 40: 3502-3507, 1980 fingerprint
LC:NCI-H322M Non-Small Cell Lung 52 M None no Small cell Bronchioalveolar Carcinoma NA 2n+/-, Near-diploid 46+/- (35-57) MT -10 35.3 NCI A.Gazdar - fingerprint
LC:NCI-H460 Non-Small Cell Lung NA M NA no Large Cell Carcinoma-ud Pleural effusion 2n+/-, Near-diploid 46+/- (35-57) WT 25 17.8 NCI J.D. Minna; A.F. Gazdar Science 246: 491-494, 1989 fingerprint
LC:NCI-H522 Non-Small Cell Lung NA M None no Adenocarcinoma-vpd NA 2n+/-, Near-diploid 46+/- (35-57) MT 16 38.2 NCI A.Gazdar Cancer Res 45: 2913-2923, 1985 fingerprint
OV:IGROV1 Ovarian 47 F Rad no Cystoadenocarcinoma-pd NA 4n+/-, Near-tetraploid 92+/- (81-103) MT 20 31 Institute Gustave Roussy, France J. Benard Cancer Res 45: 4970-4979,1985 fingerprint
OV:OVCAR-3 Ovarian 60 F CyPh/CsPt/Adr no Adenocarcinoma-md Ascites 3n+/-, Near-triploid 69+/- (58-80) MT -12 34.7 NCI T.C. Hamilton Sem Oncol 11: 285-298, 1984 fingerprint
OV:OVCAR-4 Ovarian 42 F CyPh/CsPt/Adr no Adenocarcinoma-md NA 3n+/-, Near-triploid 69+/- (58-80) WT -4 41.4 NCI T.C. Hamilton Sem Oncol 11: 285-298, 1984 fingerprint
OV:OVCAR-5 Ovarian 67 F None no Adenocarcinoma-wd NA 2n+, Hyperdiploid (47-57) MT 13 48.8 NCI R. Ozols Sem Oncol 11: 285-298, 1984 fingerprint
OV:OVCAR-8 Ovarian 64 F Ctx/Adr/CsPt/CyPh no Carcinoma-ud NA 2n+, Hyperdiploid (47-57) MT 7 26.1 NCI T.C. Hamilton Sem Oncol 11: 285-298, 1984 fingerprint
OV:SK-OV-3 Ovarian 64 F Thiotepa no Adenocarcinoma-vpd Ascites 4n+/-, Near-tetraploid 92+/- (81-103) ? 15 48.7 Memorial Sloan Kettering Cancer Center - Human Tumor Cells in vitro, pp. 115-159, 1975 fingerprint
OV:NCI/ADR-RES l Ovarian NA F NA no Adenocarinoma NA 2n+/-, Near-diploid 46+/- (35-57) MT 352 34 NCI K.Cowan, NCI Cancer Res., 46:4087-4090,1986 fingerprint
PR:PC-3 Prostate 62 M NA no Adenocarcinoma- prostate; metastatic site: bone; NA 4n, Tetraploid (92) MT 11 27.1 Pasadena Center for Medical Research M.E. Kaighn Invest Urol 1979 Jul;17(1):16-23 fingerprint
PR:DU-145 Prostate 69 M Androgen independent and unresposive to hormone therapy no prostate; metastatic site: brain; carcinoma (patient with metastatic carcinoma of the prostate and a 3 year history of lymphocytic leukemia.) Metastasis 3n+/-, Near-triploid 69+/- (58-80) ? 4 32.3 Washington University School of Medicine, Saint Louis, MO K.R. Stone Int J Cancer 21: 274-281,1978 fingerprint
RE:786-0 Renal 58 M None no Adenocarcinoma NA 4n+/-, Near-tetraploid 92+/- (81-103) MT -44 22.4 - R.D.Williams, Univ. of Iowa In Vitro 14: 779-786, 1978 fingerprint
RE:A498 Renal 52 F NA no Adenocarcinoma NA 3n, Triploid (69) WT 78 66.8 NCI - JNCI 51: 1417-1423,1973 fingerprint
RE:ACHN Renal 22 M Rad/VB/CCNU/Mto/Pred no Renal cell carcinoma-p/md NA 2n+/-, Near-diploid 46+/- (35-57) WT 120 27.5 Southern Research Inst. (T.F. Hogan, Middleton memorial VA hospital) S.M.Schmid Cancer Res 42: 4948-4953, 1982 fingerprint
RE:CAKI-1 Renal 49 M Rad/HU/5FU/Mtx/Ctx no Clear cell carcinoma Metastasis 3n, Triploid (69) WT 171 39 Memorial Sloan Kettering Cancer Center J. Fogh Human Tumor cells in vitro, pp 115-159, 1975 fingerprint
RE:RXF 393 Renal 54 M None no hypernephroma-pd NA 3n+/-, Near-triploid 69+/- (58-80) MT 42 62.9 MD Anderson Hospital and Tumor Institute NCI/DCT/DTP Contrib oncol 42, 1992 fingerprint
RE:SN12C Renal 43 M None no Renal cell carcinoma-pd NA 3n, Triploid (69) MT -86 29.5 MD Anderson Hospital and Tumor Institute .J.Fidler Cancer Res 46: 4109-4115, 1986 fingerprint
RE:TK-10 Renal 43 M None no Renal Spindle cell carcinoma NA 4n, Tetraploid (92) MT -4 51.3 - R.V.Clayman, Washington Univ.School of Medicine Cancer Res 46: 3856-3862, 1987 fingerprint
RE:UO-31 Renal NA F None no Renal cell carcinoma-vpd NA 2n+/-, Near-diploid 46+/- (35-57) WT 59 41.7 NCI W.M.Linehan Cancer Res 48:589-601, 1988 fingerprint

Footnotes:

a Information from Stinson, et al., (Anticancer Res. 1992 Jul-Aug;12(4):1035-53), DTP, ATCC, and other sources.
b Prior_Treatment: BCNU=Bis(chlorethyl)nitrosourea;CCNU=chloroethylecyclohexylnitrosourea; CyPh=cyclophosphamide;CsPt=cisplatin;Ctx=cytoxan;5FU=5-fluorouracil; Hu=hydroxyurea;Mto=mitoxantrone;Pred=prednisone;VB=vinblastine;6MP=6-mercaptopurine; Rad=radiation;Mtx=methotrexate;PiBr=piprobromine;Adr=adriamycin.
c Histology: "UD"=undifferentiated, "md"=moderately differentiated, "wd"=well differentiated, "pd"=poorly differentiated, and "vpd"=very poorly differentiated
d Ploidy information from the NCBI SKY/M-FISH and CGH Database (Roschke, et al., Cancer Res. 63 : 8634-8647, 2003)
e p53 status as determined by yeast growth functional assay: (O'Conner, et al. Cancer Res. 1997 Oct 1;57(19):4285-300).
f Multi-drug resistance (MDR) functional assay results. From DTP site (Lee, et al., Mol Pharmacol. 1994 Oct;46(4):627-38).
g Doubling times described at DPT.
h The Fingerprint calculations are described in Lorenzi et al., (Mol Cancer Ther 2009, 8(4)). To learn how to compare your DNA Fingerprint(s) to those of the NCI-60 click here.
i ME:LOX IMVI is amelanotic.
j ME:MDA-MB435 was apparently derived from the pleural effusion of a patient with breast cancer, and it has been reported to express some proteins characteristic of breast origin. However, its molecular profiles in all of our databases (transcript expression, protein expression, drug sensitivity, etc.) are absolutely characteristic of melanotic melanoma (see, e.g., Scherf, et al., Nat. Genet. 24:236 (2000); Ross, et al., ibid, 24:227 (2000)).
k ME:MDA-N was derived from ME:MDA-MB-435 by transfection with a plasmid designed to express erbB2. ME:MDA_N and ME:MDA_MB_435 are very similar under non selective conditions.
l OV:NCI/ADR-RES (called NCI-ADR-RES in DTP tabulations) was derived from OVCAR8 by culturing with Adriamycin and is classically multi-drug resistant. It was originally called, MCF7_ADR-RES, then the agnostic NCI_ADR-RES, but our SKY (Roschke, et al., Cancer Res. 63:8634 (2003)) and CGH (Bussey, et al., Mol. Ca. Ther. 5:853 (2006)) studies clearly showed its derivation from OVCAR8.

Go to top